Brand name · Prednisolone acetate
Pred Forte: adverse event reports filed with FDA
703 reports list it as a suspect or interacting product, 2004–2026. Class: Corticosteroid.
- 703
- reports as suspect product
- 0% of all reports · about 31 a year
- 39
- reports, 12 months to June 2026
- 55 in the 12 months before
- 45.9%
- marked serious by the reporter
- 77.7% across the class
- 1%
- record death among outcomes, as reported
- 7 reports · not verified by FDA
Between January 2004 and June 2026, 703 adverse event reports received by FDA list the brand name Pred Forte (prednisolone acetate) as a suspect or interacting product. Reports that mention it only as a concomitant medication (2,091) are left out of every figure here.
In the 12 months to June 2026, 39 reports listed it, down 29% from 55 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Over its reporting history that is about 31 reports a year and 0% of the 20,646,523 reports in the database, and 0.1% of the reports for the corticosteroid class. How many people take it is not in the data, so a count is not a rate of occurrence.
The MedDRA terms listed most often are drug ineffective (11.2%), off label use (11%) and intraocular pressure increased (8.4%). A report can list several reactions, so shares add to more than 100%; 187 different terms appear across these reports. Drug ineffective is recorded in 11.2% of these reports, about the same share as in the median corticosteroid drug (13.4%).
45.9% of the reports are marked serious by the reporter (77.7% across the class); 1% record death among the outcomes and 5.3% record hospitalisation, as reported. 59.2% of the reports came from consumers, and the largest patient age group is 65 to 74 (12.9%). FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."
Reports by month, five years
Reports by the month FDA received them. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.
By year received
2026 covers reports received through June 2026 only.
Reactions recorded in the reports
share of Pred Forte reports recording the termmedian drug in corticosteroid
- Drug ineffectivethe medicine did not work as expected11.2%79
- Off label useused for a purpose or in a way not on the label11%77
- Intraocular pressure increasedraised pressure in the eye8.4%59
- Eye paineye pain8.3%58
- Vision blurredblurred vision6%42
- Eye irritationeye irritation5.7%40
- Ocular hyperaemiaa red eye5.3%37
- Cataractclouding of the eye lens4.6%32
- Visual impairmentreduced vision3.4%24
- Eye disorder3%21
- Condition aggravatedthe condition being treated got worse2.8%20
- Endophthalmitisinfection inside the eye2.7%19
- No adverse eventno adverse event was reported2.7%19
- Visual acuity reducedreduced sharpness of vision2.7%19
- Glaucomaraised pressure in the eye2.3%16
- Headachehead pain2.1%15
- Corneal oedema2%14
- Eye pruritus1.8%13
- Corneal transplant1.7%12
- Eye swellinga swollen eye1.7%12
- Ocular discomfort1.7%12
- Dry eyedry eye1.6%11
- Nauseafeeling sick1.6%11
- Benign intracranial hypertension1.4%10
- Dizzinesslight-headedness or unsteadiness1.4%10
- Drug hypersensitivityan allergic-type reaction to a medicine1.4%10
- Dyspnoeashortness of breath1.4%10
- Sinusitissinus infection1.4%10
Top 30 of 187 MedDRA preferred terms recorded across these reports, with a plain-language gloss where one is available. One report can record several terms. The hollow bar is the median share across the 74 drugs in the corticosteroid class; it describes the reports, not the patients. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."
Outcomes recorded
Outcome flags as the reporter set them; a report can carry several, and "other serious" is FDA's own category for serious reports outside the named outcomes. Grey bar: all 808,789 reports in the class. FDA has not verified any outcome and states that the reports "cannot be used to estimate the incidence of these events."
Patients and reporters
Patient age
Patient sex
Who reported
Age and sex as stated in the report; the reporter's qualification is the primary source recorded by FDA. 73.3% of reports give the United States as the country of the event or reporter.
Reason for use recorded
| Indication as recorded (MedDRA) | Reports | Share |
|---|---|---|
| Postoperative care | 72 | 10.2% |
| Eye inflammation | 29 | 4.1% |
| Uveitis | 21 | 3% |
| Cataract operation | 15 | 2.1% |
| Corneal transplant | 15 | 2.1% |
| Iridocyclitis | 14 | 2% |
The indication field is filled in by the reporter and is often blank; shares are of all 703 reports.
In context
| Measure | Pred Forte | Corticosteroid | All reports |
|---|---|---|---|
| Reports as suspect product | 703 | 808,789 | 20,646,523 |
| Share of that pool | — | 0.1% | 0% |
| Reports, latest 12 months | 39 | — | 1,332,454 |
| Marked serious | 45.9% | 77.7% | 57.4% |
| Death recorded among outcomes, per 1,000 reports | 10 | 146 | 91 |
| Hospitalisation recorded, per 1,000 reports | 53 | 336 | 213 |
| Consumer-filed share | 59.2% | 29.1% | 45.8% |
| Top term, share of reports | Drug ineffective 11.2% | median 13.4% | 6.3% |
Shares are of reports, not of patients treated. The number of people taking a product is not in the data, so none of these figures is a rate, and differences between columns reflect who takes a product, who reports and how long it has been sold. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."
Other drugs in the corticosteroid class
| Drug | Name type | Reports | Latest 12 months | Marked serious |
|---|---|---|---|---|
| Prednisone | generic | 183,867 | 15,614 | 91.4% |
| Dexamethasone | generic | 129,677 | 9,216 | 95.1% |
| Prednisolone | generic | 87,806 | 6,624 | 97.6% |
| Methylprednisolone | generic | 49,537 | 4,430 | 95.2% |
| Symbicort | brand | 39,119 | 1,177 | 50.6% |
| Breo Ellipta | brand | 22,220 | 628 | 31.7% |
| Hydrocortisone | generic | 21,263 | 2,386 | 89.5% |
| Advair Diskus | brand | 20,518 | 120 | 29% |
| Advair Hfa | brand | 19,622 | 589 | 54.9% |
| Budesonide | generic | 14,714 | 1,083 | 82.2% |
| Desoximetasone | generic | 12,209 | 1,525 | 99.2% |
| Flovent | brand | 10,772 | 171 | 42.1% |
| Methylprednisolone sodium succinate | generic | 10,772 | 1,630 | 97.8% |
| Solu-medrol | generic | 10,288 | 432 | 88.8% |
| Cipro | brand | 9,791 | 108 | 57.3% |
Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." A brand and its generic are separate rows because reporters name them separately.
Questions about Pred Forte reports
How many adverse event reports has FDA received for Pred Forte?
703 reports list Pred Forte as a suspect or interacting product in the openFDA FAERS release of 28 Sep 2026, covering reports received through June 2026. 39 of them arrived in the latest 12 months. Another 2,091 list it only as a concomitant medication.
What reactions are recorded in Pred Forte reports?
drug ineffective (11.2%), off label use (11%), intraocular pressure increased (8.4%), eye pain (8.3%) and vision blurred (6%). These are MedDRA preferred terms coded from what the reporter described; a report can list several, and a term's presence is not a finding that Pred Forte was responsible.
How serious are the reports?
45.9% are marked serious by the reporter. Among the outcomes recorded, 1% of reports include death and 5.3% include hospitalisation. FDA has not verified these outcomes and states that the reports "cannot be used to estimate the incidence" of the events.
Who files these reports?
consumer or non-health professional (59.2%), physician (18.3%) and other health professional (14.4%). Most reports reach FDA through the manufacturer, which must forward reports it receives.
Are reports for Pred Forte rising?
39 reports in the 12 months to June 2026, down 29% from 55 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Counts also move with how many people take a product, its time on the market and publicity.
Do these reports show that Pred Forte was responsible for these reactions?
No. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event." The reaction may relate to the condition being treated, to other medicines, or to something else.
Is this a list of the side effects of Pred Forte?
No. It is a count of what was reported to FDA. The adverse reactions observed in clinical studies are printed on the FDA-approved label, which a pharmacist or clinician can go through with you.
How do I report an adverse event?
Consumers and health professionals can report to FDA through MedWatch (Form FDA 3500 online, or 1-800-FDA-1088), or to the manufacturer, which must pass reports on. See the guide on how to report.
Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A report counts here when it lists Pred Forte as a suspect or interacting product; reports listing it only as a concomitant medication (2,091) are excluded. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.
Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.